Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women

International Journal of Tissue Reactions

Volumn 23, Issue 1, 2001, Pages 33-37

  Gnudi, Saverio ^a   Lisi, L ^b   Fini, M ^a   Malavolta, N ^b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Department of Internal Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; HYDROXYPROLINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERANCE; FEMALE; FEMUR NECK; FOLLOW UP; HEALTH CARE AVAILABILITY; HUMAN; HYDROXYPROLINE URINE LEVEL; INJECTION PAIN; LONG TERM CARE; POSTMENOPAUSE OSTEOPOROSIS; SPINE; STATISTICAL ANALYSIS; STOMACH DISEASE;

AGED; ANALGESICS, NON-NARCOTIC; BONE DENSITY; CALCIUM; CLODRONIC ACID; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; HYDROXYPROLINE; INJECTIONS, INTRAMUSCULAR; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PHOSPHATES;

EID: 0035010665     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348, 1535, 1996.
2. Watts N.B., Harris S.T., Genant H.K., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New Engl. J. Med., 323, 73, 1990.
3. Russell R.G.G., Rogers M.J. Bisphosphonates: From the laboratory to the clinic and back again. Bone, 25(1), 97, 1999.
4. Adami S., Zamberlan N. Adverse effects of bisphosphonates: A comparative review. Drug Safety, 14, 158, 1996.
5. Khan S.A., McCloskey E.V., Nakatsuka K., Orgee J., Coombes G.M., Kanis J.A. Duration of response with oral clodronate in Paget's disease of bone. Bone, 18, 185, 1996.
6. Yates A.J.P., Percival R.C., Gray R.E.S., et al. Intravenous clodronate in the treatment and re-treatment of Paget's disease of bone. Lancet, 1, 1474, 1985.
7. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med., 339, 357, 1998.
8. Bonjour J.P., Philippe J., Guelpa G., et al. Bone and renal components in hypercalcemia of malignancy and response to a single infusion of clodronate. Bone, 9, 123, 1988.
9. Kanis J.A., McCloskey E.V., Beneton M.N. Clodronate and osteoporosis. Maturitas, 23 (Suppl.), S81, 1996.
10. Russel R.G., Rogers M.J., Frith J.C., et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res., 14(2), 53, 1999.
11. Schenk R., Merz W.A., Muhlbauer R., Russell R.G.G., Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (CI2MPD) on the calcification and resorption of cartilage and bone in the tibial epiphysis of rats. Calcif. Tissue Res., 11, 196, 1973.
12. Leppola V., Jalovaara P., Vaananen K. The influence of clodronate on the torsional strength of the growing rat tibia in immobilisation osteoporosis. Bone, 15(3), 367, 1994.
13. Kaastad T.S., Reikeras O., Madsen J.E., et al. Effects of clodronate on cortical and trabecular bone in ovariectomized rats on a low calcium diet. Calcif. Tissue Int., 61(2), 158, 1997.
14. Giannini G., D'Angelo A., Sartori L., Passeri G., Dalle Carbonare L., Crepaldi G. Continuous and cyclical clodronate therapies and bone. Obstet. Gynecol., 88(3), 431, 1996.
15. Herrala J., Puolijoki H., Liippo K., et al. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone, 22(5), 577, 1998.
16. Tsai K.S., Hsu S.H., Yang R.S., Cheng W.C., Chieng P.U. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women. Calcif. Tissue Int., 64(5), 384, 1999.
17. Giannini S., D'Angelo A., Malavasi L., et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone, 14(2), 137, 1993.
18. Filipponi P., Pedretti M., Fedeli L., et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy. J. Bone Miner. Res., 10(5), 697, 1995.
19. Rossini M., Braga V, Gatti D., Gerardi D., Zamberlan N., Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone, 24(2), 125, 1999.
20. Harris S.T., Watts N.B., Genant H.K., et al. Effects of residronete treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomised controlled trial. Vertebral Efficacy with Residronete Therapy (VERT) Study Group. JAMA, 282 (14), 1344, 1999.
21. Fromm G.A., Vega E., Plantalech L., Galich A.M., Mautalen C.A. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int., 1, 129, 1991.